SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Early stage breast cancer. Consens Statement. 1990; 8: 119.
  • 2
    Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer. 2000; 88: 10991107.
  • 3
    Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol. 2002; 9: 745753.
  • 4
    Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000; 18: 25532559.
  • 5
    Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349: 546553.
  • 6
    Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000; 88: 608614.
  • 7
    Roumen RM, Kuijt GP, Liem IH, van Beek MW. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg. 2001; 88: 16391643.
  • 8
    Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol. 2001; 77: 165170.
  • 9
    Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg. 2003; 138: 482487; discussion 87–88.
  • 10
    Chung MA, Steinhoff MM, Cady B. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am J Surg. 2002; 184: 310314.
  • 11
    Reitsamer R, Peintinger F, Prokop E, Menzel C, Cimpoca W, Rettenbacher L. Sentinel lymph node biopsy alone without axillary lymph node dissection-follow up of sentinel lymph node negative breast cancer patients. Eur J Surg Oncol. 2003; 29: 221223.
  • 12
    Badgwell BD, Povoski SP, Abdessalam SF, et al. Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann Surg Oncol. 2003; 10: 376380.
  • 13
    Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004; 240: 462468; discussion 68–71.
  • 14
    Fant JS, Grant MD, Knox SM, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003; 10: 126130.
  • 15
    Guenther JM, Hansen NM, DiFronzo A, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003; 138: 5256.
  • 16
    Fisher B, Heong JH, Anderson S, Wolmark N. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project Clinical Trials. J Natl Cancer Inst. 2004; 96: 18231831.
  • 17
    deBoer R, Hillen HFP, Roumen RMH, Rutten HJT, van der Sangen MJC, Voogd AC. Detection, treatment and outcome of axillary recurrence after axillary clearance for invasive breast cancer. Br J Surg. 2001; 88: 118122.
  • 18
    Harris EER, Hwang WT, Seyednejad F, Solin LJ. Prognosis after regional lymph node recurrence in patients with stage I–II breast carcinoma treated with breast conservation therapy. Cancer. 2003; 98: 21442151.
  • 19
    Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1991; 9: 988996.
  • 20
    Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol. 2004; 22: 97101.
  • 21
    Wong SL, Abell TD, Chao C, Edwards MJ, McMasters KM. Optimal use of sentinel lymph node biopsy versus axillary lymph node dissection in patients with breast carcinoma. Cancer. 2002; 95: 478487.
  • 22
    Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg. 2000; 232: 17.
  • 23
    Wong SL, Edwards MJ, Chao C, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001; 192: 684691.
  • 24
    White RL, Wilke LG. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg. 2004; 70: 420424.
  • 25
    GreeneFL, PageDL, FlemingID, et al., editors. AJCC cancer staging handbook. 6th ed. New York: Springer-Verlag, 2002.
  • 26
    Chagpar A, Middleton LP, Sahin AA, et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005; 103: 15811586.
  • 27
    Fisher B, Jeong JH, Anderson S, et al. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002; 347: 567575.